Genetic test to determine non-responsiveness to statin drug treatment
    32.
    发明授权
    Genetic test to determine non-responsiveness to statin drug treatment 失效
    确定对他汀类药物治疗无反应的遗传试验

    公开(公告)号:US06297014B1

    公开(公告)日:2001-10-02

    申请号:US09347114

    申请日:1999-07-02

    IPC分类号: C12Q168

    CPC分类号: C12Q1/6883 C12Q2600/156

    摘要: In a method for detecting a genetic predisposition in a human for non-responsiveness to statin drug treatment for coronary artery disease, nucleic acids comprising nucleotide sequences of the human lipoprotein lipase (LPL) gene are amplified and analyzed. Homozygosity for a variant allele in a non-coding or untranslated region of the 3′ end of LPL, for example, LPL HindIII 2/2 or (TTTA)n 4/4 genotypes, is linked to non-responsiveness to treatment with statin drugs, including lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, or cerivastatin. Oligonucleotide primer sequences, primer sets, and genetic testing kits allow the practitioner to practice the method and thus better individualize the treatment and improve the care of patients with coronary artery disease.

    摘要翻译: 在用于检测对于冠状动脉疾病的他汀类药物治疗的非反应性的人的遗传易感性的方法中,扩增并分析了包含人脂蛋白脂肪酶(LPL)基因的核苷酸序列的核酸。 在LPL 3'末端的非编码区或非翻译区,例如LPL HindIII 2/2或(TTTA)n 4/4基因型中的变体等位基因的纯合性与对他汀类药物治疗的无反应性有关 ,包括洛伐他汀,普伐他汀,辛伐他汀,阿托伐他汀,氟伐他汀或西立伐他汀。 寡核苷酸引物序列,引物组和遗传测试试剂盒使得从业者能够实施该方法,从而更好地个体化治疗并改善冠状动脉疾病患者的护理。